Grant: Engage Grants Program
University of Toronto
$25,000.00
Validation of small molecule targets in alpha-synuclein neurotoxicity pathways
EF 2012-13
Résumé
The proposed research aims to test the capacity of two classes of small molecules to clear aggregation of proteins in the neurons of the fruitfly, Drosophila melanogaster. One class of proteins are topoisomerase inhibitors, which interfere with DNA synthesis and translation, and have industrial use as cancer therapeutics and pesticides. The second class are beta-glycyrrhetinic acid analogs, which have multiple properties including modification of hormonal metabolic enzymes, antiviral, antibacterial, antifungal, and antiprotozoal activities. We will test the capacity of these compounds to clear alpha-synuclein, a protein that is susceptible to forming aggregates in neural cells over time and through injury. We will also assess the changes in cellular physiological status in response to exposure to these compounds. Specifically, we will detect changes in cell survival as well as cell morphology, which is a readout of cellular health. The outcome of this research will be informative for the development of industrial application of these compounds. If the compounds show strong protein clearance activity, they will be studied further for their potential application to neurodegeneration therapeutics. If the compounds demonstrate little or no protein clearance activity, yet show powerful suppressors of cell division in the insect model, they may be studied further for their potential use as pesticides.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
435698-2012
Name nom
Boulianne, Gabrielle
Department département
Head Office
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2012
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
6400
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Life sciences research related to human health and disease
Research subject fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Partie
1
Nb partie
1
Application title
Validation of small molecule targets in alpha-synuclein neurotoxicity pathways
Keyword
NSERC
Application summary
The proposed research aims to test the capacity of two classes of small molecules to clear aggregation of proteins in the neurons of the fruitfly, Drosophila melanogaster. One class of proteins are topoisomerase inhibitors, which interfere with DNA synthesis and translation, and have industrial use as cancer therapeutics and pesticides. The second class are beta-glycyrrhetinic acid analogs, which have multiple properties including modification of hormonal metabolic enzymes, antiviral, antibacterial, antifungal, and antiprotozoal activities. We will test the capacity of these compounds to clear alpha-synuclein, a protein that is susceptible to forming aggregates in neural cells over time and through injury. We will also assess the changes in cellular physiological status in response to exposure to these compounds. Specifically, we will detect changes in cell survival as well as cell morphology, which is a readout of cellular health. The outcome of this research will be informative for the development of industrial application of these compounds. If the compounds show strong protein clearance activity, they will be studied further for their potential application to neurodegeneration therapeutics. If the compounds demonstrate little or no protein clearance activity, yet show powerful suppressors of cell division in the insect model, they may be studied further for their potential use as pesticides.